BQ-123 Clinical Trials

Size	Price	Qty
1mg	USD 147
5mg	USD 397

Clinical Trials

Numerous clinical trials evaluate BQ-123 across various cardiovascular, metabolic, and renal conditions, including coronary artery disease, hypertension, myocardial reperfusion injury, chronic kidney disease, and type 1 diabetes. Spanning early phase 1 through phase 4, these studies are sponsored by academic and clinical research institutions such as the Medical University of Vienna, Mayo Clinic, and the University of Edinburgh. Across the trial portfolio, recruitment statuses encompass completed, actively recruiting, unknown, and withdrawn studies.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02966665	RECRUITING	Chronic Obstructive Pulmonary Disease; Pulmonary Artery Hypertension; Heart Failure; Hypertension	Russell Richardson	2008-09	PHASE1
NCT03679780	COMPLETED	Cardiovascular Diseases; Cardiovascular Risk Factor; Vasoconstriction	The University of Texas at Arlington	2018-10-01	PHASE1
NCT04907838	UNKNOWN	Type2 Diabetes	University of Southern Denmark	2018-05-01
NCT01119417	WITHDRAWN	Hypertension; Pure Autonomic Failure; Multiple System Atrophy	Vanderbilt University	2010-05	PHASE1
NCT04449198	Recruiting	Type 1 Diabetes	Augusta University	2020-10-14	Early Phase 1
NCT02062346	COMPLETED	Vasculitis	University of Edinburgh	2016-08
NCT02124824	COMPLETED	Heart Failure	VA Office of Research and Development	2014-09-01	EARLY_PHASE1
NCT01395329	COMPLETED	Prehypertension; Hypertension	University of Colorado, Boulder	2011-05	PHASE4
NCT01658410	UNKNOWN	Coronary Artery Disease; Aorto-coronary Bypass Grafting	Medical University of Vienna	2012-07	PHASE2
NCT02086253	COMPLETED	Healthy Conditions	University Hospital, Rouen	2014-02
NCT00586820	COMPLETED	Myocardial Reperfusion Injury	Mayo Clinic	2005-05	PHASE2
NCT00915070	COMPLETED	Healthy	Medical University of Vienna	2010-10
NCT00759408	COMPLETED	Pulmonary Hypertension	Brigham and Women's Hospital	1999-02	PHASE2
NCT00502528	COMPLETED	ST-Elevation Myocardial Infarction	Medical University of Vienna	2007-05	PHASE2
NCT00745693	COMPLETED	Coronary Disease	University of Edinburgh	2008-03
NCT00745693	Completed	Coronary Disease	University of Edinburgh\|Umeå University	2008-03	Not Applicable
NCT00722215	COMPLETED	Chronic Kidney Disease; Proteinuria	University of Edinburgh	2006-05	PHASE1
NCT00115583	COMPLETED	Atherosclerosis, Coronary	Brigham and Women's Hospital	1998-11
NCT00427232	COMPLETED	Coronary Vessels; Endothelins; Vascular Resistance	Medical University of Vienna	2003-05	PHASE1

(data from https://clinicaltrials.gov, updated on 2025-09-26)

Check the BQ-123 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

BQ-123 acts as a selective endothelin A (ETA) receptor antagonist that binds to ETA receptors, thereby inhibiting endothelin-1-induced intracellular calcium mobilization and downstream vasoconstrictive signaling cascades. This molecular blockade leads to vascular smooth muscle relaxation and enhanced blood flow, providing therapeutic relevance for treating elevated vascular resistance in cardiovascular diseases such as hypertension, coronary artery disease, and pulmonary arterial hypertension.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).